| Coverage Decisions for Medical Technologies & Procedures |  | |
Brevio® Nerve Conduction Testing System
Coverage decision
The Brevio® Nerve Conduction Testing System is not covered at this time. L&I reviewed the scientific literature and determined there is not sufficient evidence of efficacy for this diagnostic tool. Brevio® is considered investigational and experimental.
This coverage decision applies to all State Fund and self-insured claims in all locations.
Background
The NeuMed Brevio is a handheld device intended for use in evaluating nerve function. Similar to conventional nerve conduction study devices, the Brevio® assesses function via surface electrodes. This evidence does not support the accuracy or reliability of Nervepace for use as a diagnostic or screening tool for any condition(s) and specifically for carpal tunnel syndrome.
Billing information
Nerve conduction tests performed with Brevio® do not have unique billing codes at this time. The manufacturer of Brevio® recommends use of CPT codes:
- 95900,
- 95903,
- 95904.
These codes apply to billing for motor nerve testing, motor nerve testing with F-waves and sensory nerve testing.
Note: These codes are approved only for nerve conduction studies performed with traditional nerve conduction testing systems.
In accordance with WAC 296-20-03002, L&I will not pay for treatment which is considered experimental in nature. L&I may recoup payments plus interest for nerve conduction tests paid inappropriately.
For more information:
Brevio® Assessment (24 KB PDF)
WAC 296-20-02704 - What criteria does the director or director's designee use to make medical coverage decisions?
WAC 296-20-02850 - When may L&I cover controversial, obsolete, investigational or experimental treatment?
